Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 1, 2011, Pages 111-114

  Taupin, Philippe ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Biomarker; Cell surface antigen; Lymphoma; Neurological disease; Therapy

Indexed keywords

RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CEREBROSPINAL FLUID; CONTINUOUS INFUSION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; MULTIPLE SCLEROSIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATENTS AS TOPIC; TIME FACTORS;

EID: 78650490588     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.530253     Document Type: Article

References (30)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16
2. Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 2007;20:269-74
3. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-8
4. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129:595-605
5. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35
6. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8
7. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004;18:379-96
8. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-82
9. Lunde Larsen LS, Larsson HB, Frederiksen JL. The value of conventional high-field MRI in MS in the light of the McDonald criteria: a literature review. Acta Neurol Scand 2010;122:149-58
10. Angelucci F, Mirabella M, Frisullo G, et al. Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. Dis Markers 2005;21:49-55
11. Rentzos M, Cambouri C, Rombos A, et al. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 2006;241:25-9
12. Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008;3:e2559
13. Tumani H, Hartung HP, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009;35:117-27
14. Mandrioli J, Sola P, Bedin R, et al. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008;255:1023-31
15. Clark EA, Shu G, Ledbetter JA. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 1985;82:1766-70
16. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76
17. Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010;267:260-77
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
19. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61
20. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
21. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803-43
22. Held G, Poschel V, Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006;6:1175-86
23. Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol 2009;27:1009-16
24. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009;2:6609
25. Dalakas MC. Pathogenesis and treatment of Anti-MAG neuropathy. Curr Treat Options Neurol 2010;12:71-83
26. Taupin P. Transplantation of cord blood stem cells for treating hematologic diseases and strategies to improve engraftment. Therapy 2010; In press
27. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010;67:707-14
28. Taupin P. Thirteen compounds promoting oligodendrocyte progenitor cell differentiation and remyelination for treating multiple sclerosis: WO2010054307. Expert Opin Ther Pat 2010; In press
29. Taupin P. Adult neurogenesis and neural stem cells as a model for the discovery and development of novel drugs. Expert Opin Drug Discov 2010;5:921-25
30. Taupin P. Neurogenic drugs and compounds. Recent Pat CNS Drug Discov 2010;5:253-7